A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
Abstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants si...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | Addiction Science & Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13722-021-00278-y |
| _version_ | 1818750969212567552 |
|---|---|
| author | Caroul Chawar Alannah Hillmer Stephanie Sanger Alessia D’Elia Balpreet Panesar Lucy Guan Dave Xiaofei Xie Nandini Bansal Aamna Abdullah Flavio Kapczinski Guillaume Pare Lehana Thabane Zainab Samaan |
| author_facet | Caroul Chawar Alannah Hillmer Stephanie Sanger Alessia D’Elia Balpreet Panesar Lucy Guan Dave Xiaofei Xie Nandini Bansal Aamna Abdullah Flavio Kapczinski Guillaume Pare Lehana Thabane Zainab Samaan |
| author_sort | Caroul Chawar |
| collection | DOAJ |
| description | Abstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. Objectives This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. Methods Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. Results Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10–7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. Limitations The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. Conclusion The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121. |
| first_indexed | 2024-12-18T04:28:07Z |
| format | Article |
| id | doaj.art-5cb8c8e6c2a944c5a05ed746c8958567 |
| institution | Directory Open Access Journal |
| issn | 1940-0640 |
| language | English |
| last_indexed | 2024-12-18T04:28:07Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Addiction Science & Clinical Practice |
| spelling | doaj.art-5cb8c8e6c2a944c5a05ed746c89585672022-12-21T21:21:02ZengBMCAddiction Science & Clinical Practice1940-06402021-11-0116111410.1186/s13722-021-00278-yA systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorderCaroul Chawar0Alannah Hillmer1Stephanie Sanger2Alessia D’Elia3Balpreet Panesar4Lucy Guan5Dave Xiaofei Xie6Nandini Bansal7Aamna Abdullah8Flavio Kapczinski9Guillaume Pare10Lehana Thabane11Zainab Samaan12Neuroscience Graduate Program, McMaster UniversityNeuroscience Graduate Program, McMaster UniversityHealth Sciences Library, McMaster UniversityNeuroscience Graduate Program, McMaster UniversityNeuroscience Graduate Program, McMaster UniversityDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare HamiltonDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare HamiltonDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare HamiltonDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare HamiltonDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare HamiltonPopulation Health Research InstitutePopulation Health Research InstituteDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare HamiltonAbstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. Objectives This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. Methods Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. Results Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10–7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. Limitations The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. Conclusion The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121.https://doi.org/10.1186/s13722-021-00278-yOpioidPharmacogeneticMOUDMethadoneGWASSystematic review |
| spellingShingle | Caroul Chawar Alannah Hillmer Stephanie Sanger Alessia D’Elia Balpreet Panesar Lucy Guan Dave Xiaofei Xie Nandini Bansal Aamna Abdullah Flavio Kapczinski Guillaume Pare Lehana Thabane Zainab Samaan A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder Addiction Science & Clinical Practice Opioid Pharmacogenetic MOUD Methadone GWAS Systematic review |
| title | A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder |
| title_full | A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder |
| title_fullStr | A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder |
| title_full_unstemmed | A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder |
| title_short | A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder |
| title_sort | systematic review of gwas identified snps associated with outcomes of medications for opioid use disorder |
| topic | Opioid Pharmacogenetic MOUD Methadone GWAS Systematic review |
| url | https://doi.org/10.1186/s13722-021-00278-y |
| work_keys_str_mv | AT caroulchawar asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alannahhillmer asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT stephaniesanger asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alessiadelia asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT balpreetpanesar asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lucyguan asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT davexiaofeixie asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT nandinibansal asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT aamnaabdullah asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT flaviokapczinski asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT guillaumepare asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lehanathabane asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT zainabsamaan asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT caroulchawar systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alannahhillmer systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT stephaniesanger systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alessiadelia systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT balpreetpanesar systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lucyguan systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT davexiaofeixie systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT nandinibansal systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT aamnaabdullah systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT flaviokapczinski systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT guillaumepare systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lehanathabane systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT zainabsamaan systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder |